Northwest & Ethical Investments L.P. Increases Position in Boston Scientific Co. (NYSE:BSX)

Northwest & Ethical Investments L.P. grew its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 91.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 74,098 shares of the medical equipment provider's stock after acquiring an additional 35,336 shares during the quarter. Northwest & Ethical Investments L.P.'s holdings in Boston Scientific were worth $6,210,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Boston Scientific by 4.4% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider's stock worth $345,205,000 after purchasing an additional 173,034 shares during the period. BDF Gestion purchased a new position in Boston Scientific during the second quarter valued at $3,570,000. Cetera Advisor Networks LLC lifted its position in shares of Boston Scientific by 11.8% in the first quarter. Cetera Advisor Networks LLC now owns 201,426 shares of the medical equipment provider's stock worth $13,796,000 after buying an additional 21,252 shares in the last quarter. Brookstone Capital Management grew its holdings in shares of Boston Scientific by 389.1% in the second quarter. Brookstone Capital Management now owns 69,945 shares of the medical equipment provider's stock valued at $5,414,000 after purchasing an additional 55,645 shares in the last quarter. Finally, HWG Holdings LP bought a new stake in shares of Boston Scientific in the 2nd quarter worth about $482,000. Institutional investors own 89.07% of the company's stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the business's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now owns 978 shares of the company's stock, valued at $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total value of $570,511.10. Following the transaction, the executive vice president now owns 37,468 shares of the company's stock, valued at $3,061,135.60. This trade represents a 15.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 328,157 shares of company stock worth $27,894,270 in the last quarter. Company insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on BSX shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Boston Scientific in a research note on Wednesday. Bank of America upped their price objective on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a "buy" rating in a research note on Tuesday, October 22nd. Royal Bank of Canada lifted their price target on Boston Scientific from $95.00 to $98.00 and gave the company an "outperform" rating in a report on Thursday, October 24th. Morgan Stanley increased their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the company an "overweight" rating in a research report on Thursday, October 24th. Finally, Raymond James boosted their price target on Boston Scientific from $91.00 to $94.00 and gave the stock a "strong-buy" rating in a research note on Wednesday, September 4th. Four research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $93.39.

Boston Scientific Price Performance

Shares of NYSE BSX traded down $0.09 during trading on Friday, hitting $90.66. The company had a trading volume of 3,446,971 shares, compared to its average volume of 6,066,885. Boston Scientific Co. has a fifty-two week low of $53.93 and a fifty-two week high of $91.93. The stock has a fifty day simple moving average of $86.70 and a two-hundred day simple moving average of $80.71. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $133.62 billion, a price-to-earnings ratio of 74.93, a price-to-earnings-growth ratio of 2.67 and a beta of 0.79.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The firm had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same period last year, the firm posted $0.50 earnings per share. The company's revenue for the quarter was up 19.3% on a year-over-year basis. On average, research analysts expect that Boston Scientific Co. will post 2.46 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.